Aldesleukin
Aldesleukin 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Metastatic Colorectal Cancer、Metastatic Pancreatic Cancer、Metastatic Ovarian Cancer、Metastatic Breast Carcinoma。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
0 项
已进入 III/IV 期
7 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- National Cancer Institute (NCI)
- Aulos Bioscience, Inc.
- University of Chicago
- Dana-Farber Cancer Institute
- University Hospital, Basel, Switzerland
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- The First Affiliated Hospital of Xiamen University
- Karam Khaddour, MD, MS
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、瑞士、中国、澳大利亚、英国、丹麦、中国香港
正在招募患者的 Aldesleukin 研究
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
II 期招募中美国NCT02133196A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
II 期招募中美国NCT02621021A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.
I 期 / II 期招募中美国NCT07389239Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
I 期招募中美国NCT06138587TIL Therapy in Non-small-cell Lung Cancer (NSCLC) Patients
II 期招募中瑞士NCT06455917Treatment of Refractory cGVHD by Donor-derived Treg Cell Injection Combined With Recombinant Human Interleukin-2
早期 I 期招募中中国NCT06920199Thymalfasin and Recombinant Human IL-2 Injections in Treating Lymphocytopenia for Patients With Malignant Hematological Tumors
II 期招募中中国NCT06584006TIL Therapy in cSCC and MCC
II 期招募中美国NCT07288073Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
I 期 / II 期招募中美国澳大利亚NCT05267626Low Dose IL-2 for the Treatment of Crohn's Disease
I 期 / II 期招募中美国NCT04263831Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease
I 期 / II 期招募中美国NCT07651319Low-dose Interleukin-2 After Myocardial Infarction to Investigate Effects on Tissue-resident Regulatory T Cells
不适用招募中英国NCT07610538Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease
I 期招募中美国NCT07192900To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma
I 期招募中丹麦NCT06204991Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors
I 期招募中美国NCT07443020IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
I 期 / II 期招募中美国NCT06119685E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
II 期招募中美国NCT05686226CIML NK Cells With Venetoclax for AML
I 期招募中美国NCT06152809Quadruple Immunotherapy for Neuroblastoma
II 期招募中中国香港NCT05754684A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia
I 期招募中美国NCT07011004Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
II 期招募中美国NCT01174121KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
I 期招募中美国NCT05483491E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
I 期 / II 期招募中美国NCT05639972Low-Dose IL-2 For The Reduction Of Vascular Inflammation In ACS -Clinical Outcomes & Follow-up Study
不适用招募中英国NCT06427694
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。